...
首页> 外文期刊>British Journal of Cancer >Prognostic factors in metaplastic carcinoma of the breast: a multi-institutional study
【24h】

Prognostic factors in metaplastic carcinoma of the breast: a multi-institutional study

机译:乳腺增生癌的预后因素:多机构研究

获取原文

摘要

Background: Metaplastic breast carcinoma (MBC) is a rare type of breast cancer that has basal-like characteristics and is perceived to have poorer prognosis when compared with conventional no specific type/ductal carcinomas (ductal/NST). However, current data on MBC are largely derived from small case series or population-based reports. This study aimed to assess the clinicopathological features and outcome of MBC identified through an international multicentre collaboration. Methods: A large international multicentre series of MBC (no=405) with histological confirmation and follow-up information has been included in this study. The prognostic value of different variables and outcome has been assessed and compared with grade, nodal status and ER/HER2 receptor-matched ductal/NST breast carcinoma. Results: The outcome of MBC diagnosed in Asian countries was more favourable than those in Western countries. The outcome of MBC is not different from matched ductal/NST carcinoma but the performance of the established prognostic variables in MBC is different. Lymph node stage, lymphovascular invasion and histologic subtype are associated with outcome but tumour size and grade are not. Chemotherapy was associated with longer survival, although this effect was limited to early-stage disease. In this study no association between radiotherapy and outcome was identified. Multivariate analysis of MBC shows that histologic subtype is an independent prognostic feature. Conclusions: This study suggests that MBC is a heterogeneous disease. Although the outcome of MBC is not different to matched conventional ductal/NST breast carcinoma, its behaviour is dependent on the particular subtype with spindle cell carcinoma in particular has an aggressive biological behaviour. Management of patients with MBC should be based on validated prognostic variables.
机译:背景:化生性乳腺癌(MBC)是一种罕见的乳腺癌,具有基底样特征,与常规的非特异性/导管癌(导管/ NST)相比,预后较差。但是,有关MBC的当前数据主要来自小病例系列报告或基于人群的报告。这项研究旨在评估通过国际多中心合作确定的MBC的临床病理特征和结局。方法:本研究包括一个大型的国际多中心MBC系列(no = 405),具有组织学确认和随访信息。评估了不同变量和预后的预后价值,并将其与等级,淋巴结状态和ER / HER2受体匹配的导管/ NST乳腺癌进行了比较。结果:亚洲国家诊断出的MBC的结果比西方国家要好。 MBC的结局与匹配的导管癌/ NST癌无异,但已建立的MBC预后变量的表现不同。淋巴结分期,淋巴管浸润和组织学亚型与预后相关,但肿瘤大小和等级无关。化学疗法与更长的生存期相关,尽管这种作用仅限于早期疾病。在这项研究中,没有发现放疗与预后之间的关联。 MBC的多变量分析表明,组织学亚型是独立的预后特征。结论:这项研究表明MBC是一种异质性疾病。尽管MBC的结果与匹配的常规导管癌/ NST乳腺癌并无不同,但其行为取决于梭形细胞癌的特定亚型,尤其具有侵略性的生物学行为。 MBC患者的治疗应基于经过验证的预后变量。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号